AZ, Illumina join forces to develop companion diagnostic tests for cancer drugs
- Illumina's next-generation sequencing (NGS) technology makes it possible to rapidly sequence multiple genes much faster and cheaper than traditional DNA sequencing.
- In terms of using NGS-based companion diagnostic tests in practice, NGS will be used to screen a panel of several gene sequences. The information will then be used to predict patients’ responses to various treatments.
- The goal for AstraZeneca is to develop companion-diagnostic tests to accompany specific oncology medications.
Illumina’s technology has caught the attention of the biopharmaceutical community. In addition to inking this deal with AstraZeneca, in July, Illumina was chosen by Genomics England, which is owned by the Department of Health in the UK, to take on the 100,000 Genomes Project---a project that is worth almost $500 million.
- pharmafile.com AstraZeneca and Illumina in new partnership